Association of Disease Duration and Duration of Olanzapine Use with Blood Sugar, Blood Pressure, BMI, and Lipid Profile among Schizophrenic Patients in Iraq
DOI:
https://doi.org/10.54133/ajms.v4i.119Keywords:
Olanzapine, Blood sugar, Blood pressure, Lipid profile, Schizophrenic patientsAbstract
Background: The association of olanzapine with hyperglycemia, an elevated lipid profile, and high blood pressure was early recognized after its approval and has become of increased concern. Objective: To determine the association of olanzapine use with blood sugar levels, lipid profiles, and blood pressure in hospitalized Iraqi patients with schizophrenia. Methods: A cross-sectional study involving 50 hospitalized patients with schizophrenia who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-V diagnostic criteria and had taken olanzapine for at least two years was carried out between November 2022 and February 2023 at two facilities in Baghdad, Iraq (Ibn Rushd Psychiatric Teaching Hospital and Al Rashad Hospital for Mental Health). Blood pressure, fasting blood sugar, and serum lipid profile (triglycerides [TG], high-density lipoprotein [HDL], low-density lipoprotein [LDL], and very-low-density lipoprotein [VLDL]) were measured at baseline and after olanzapine use. Results: Olanzapine significantly increases fasting blood glucose (P< 0.001). After using olanzapine, both systolic and diastolic blood pressures significantly increased. It significantly increased the levels of cholesterol, triglycerides, and VLDL (P<0.001). Moreover, HDL levels were drastically lowered. The current investigation found no significant link between the patient's waist circumference and current weight and the length of their illness or olanzapine use. In addition, there was no association between the duration of olanzapine use and blood sugar, blood pressure, or lipid profiles. Conclusion: Different doses and durations of olanzapine use in Iraqi schizophrenic patients are associated with a negative impact on glycemic control, blood pressure, and lipid profiles.
Downloads
References
Chen Y, Wang Y, Fang X, Zhang Y, Song L, Zhang C. Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis. Gen Psychiatr. 2020;33(3):e100192. doi: 10.1136/gpsych-2020-100192. DOI: https://doi.org/10.1136/gpsych-2020-100192
Gupta A, Jadhav A, Dubey V. Comparison of serum lipid profile changes during treatment of olanzapine and risperidone. Int J Life-Sci Sci Res. 2017;3(5):1283-1286. DOI: https://doi.org/10.21276/ijlssr.2017.3.5.3
Jackson M, Delp C, Bindschadler D, Sarrel M, Wollaeger R, Lam D. Dynamic gate product and artifact generation from system models. IEEE J. 2011;11944045:1-10. doi: 10.1109/AERO.2011.5747541. DOI: https://doi.org/10.1109/AERO.2011.5747541
Mednova IA, Kornetova EG, Ivanovа SA. Model for predicting metabolic syndrome in patients with paranoid schizophrenia. Siberian Herald Psychiatr Addict Psychiatr. 2020;3(108):45-50. doi: 10.26617/1810-3111-2020-3(108)-45-50. DOI: https://doi.org/10.26617/1810-3111-2020-3(108)-45-50
Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl). 2005;183(3):383-386. doi: 10.1007/s00213-005-0205-2. DOI: https://doi.org/10.1007/s00213-005-0205-2
Saddichha S, Vishnuvardhan G, Akhtar S. Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia. Int J Risk Saf Med. 2011;23(3):181-185. doi: 10.3233/JRS-2011-0536. DOI: https://doi.org/10.3233/JRS-2011-0536
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-2241. doi: 10.2147/NDT.S113099. DOI: https://doi.org/10.2147/NDT.S113099
Al-Thanoon ZA, Mahmood IH. Metabolic changes caused by first generation antipsychotic versus second generation antipsychotic in schizophrenic patients. J Pharm Rese. 2013;7(6):468–471. doi: 10.1016/j.jopr.2013.06.016. DOI: https://doi.org/10.1016/j.jopr.2013.06.016
Mandrioli R, Protti M, Mercolini L. Metabolic syndrome in schizophrenia: Focus on the role of antipsychotic medications and indications for therapeutic drug monitoring (TDM) methods. Front Clin Drug Res Diabetes Obes. 2020;5:1-65. DOI: https://doi.org/10.2174/9781681087535120050003
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). Washington, DC; 2013. DOI: https://doi.org/10.1176/appi.books.9780890425596
Kasanin J. The blood sugar curve in mental disease. Arch NeurPsych. 1926;16(4):414-419. doi:10.1001/archneurpsyc.1926.02200280022002. DOI: https://doi.org/10.1001/archneurpsyc.1926.02200280022002
Liu JH, Chen N, Guo YH, Guan XN, Wang J, Wang D, et al. Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. J Psychiatr Res. 2021;140:409-415. doi: 10.1016/j.jpsychires.2021.06.001. DOI: https://doi.org/10.1016/j.jpsychires.2021.06.001
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100. PMID: 11247108. DOI: https://doi.org/10.4088/JCP.v62n0204
Woo YS, Kim W, Chae JH, Yoon BH, Bahk WM. Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry. 2009;10(4 Pt 2):420-425. doi: 10.1080/15622970801910399. DOI: https://doi.org/10.1080/15622970801910399
Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol. 2003;13(3):311-317. doi: 10.1089/104454603322572642. DOI: https://doi.org/10.1089/104454603322572642
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296. doi: 10.1176/appi.ajp.160.2.290. DOI: https://doi.org/10.1176/appi.ajp.160.2.290
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. doi: 10.1176/ajp.2007.164.7.1050. DOI: https://doi.org/10.1176/ajp.2007.164.7.1050
Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325(7358):243. doi: 10.1136/bmj.325.7358.243. DOI: https://doi.org/10.1136/bmj.325.7358.243
Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41(3):337-343. doi: 10.1097/00004583-200203000-00014. DOI: https://doi.org/10.1097/00004583-200203000-00014
Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53(17):2079-2081. doi: 10.1093/ajhp/53.17.2079.. DOI: https://doi.org/10.1093/ajhp/53.17.2079
Leard-Hansson J, Guttmacher L. Antipsychotic-associated weight gain. Clin Psychiat News. 2005;33(6):23. DOI: https://doi.org/10.1016/S0270-6644(05)70424-0
Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, et al. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosom Med. 1967;29(6):634-642. doi: 10.1097/00006842-196711000-00008. DOI: https://doi.org/10.1097/00006842-196711000-00008
Lee JS, Kwon JS, Kim D, Kim S-W, Kim J-J, Kim J-H, et al. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. Psychiatr Invest. 2017;14(1):44. doi: 10.4306/pi.2017.14.1.44. DOI: https://doi.org/10.4306/pi.2017.14.1.44
Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001;158(10):1719-1722. doi: 10.1176/appi.ajp. DOI: https://doi.org/10.1176/appi.ajp.158.10.1719
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. doi: 10.1176/ajp.156.11.1686. DOI: https://doi.org/10.1176/ajp.156.11.1686
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1-6. doi: 10.1097/01.hco.0000200416.65370.a0. DOI: https://doi.org/10.1097/01.hco.0000200416.65370.a0
Maslov B, Babić D, Zovko N. Ipact of psychopharmaca on the frequency of metabolic syndrome in patients with schizophrenia. Psychiatria Danubina. 2009;21(1):137.
Pandya S. Antipsychotics: uses, actions and prescribing rationale. Nurse Prescrib. 2009;7(1):23-27. doi: 10.12968/npre.2009.7.1.38630. DOI: https://doi.org/10.12968/npre.2009.7.1.38630
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
